Cohance Lifesciences Withdraws CRISIL Ratings on Certain Facilities
Cohance Lifesciences has requested the withdrawal of its CRISIL credit ratings for certain lower-limit facilities, stating they are covered by India Ratings. The company confirmed no impact on existing facilities. CRISIL noted the withdrawal was at the company's request and cited 'issuer not cooperating' in its rationale for previously downgraded ratings on ₹72.5 crore facilities.
The company explicitly states that the withdrawal of these specific CRISIL ratings has no impact on its existing credit facilities or borrowing arrangements, as these are covered by other valid ratings. Therefore, the direct financial or operational impact is considered low.
The announcement is a routine regulatory filing regarding the withdrawal of credit ratings. While the company states there is no impact, the context provided by CRISIL Ratings about 'issuer not cooperating' and previous downgrades introduces a neutral to slightly negative undertone, but the core message is factual.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has informed the stock exchanges about the withdrawal of certain credit ratings assigned by CRISIL Ratings Limited. This withdrawal was made at the company's request and pertains to lower-limit facilities.
The company clarified that these facilities are adequately covered by the credit ratings provided by India Ratings and Research Private Limited for its higher-limit credit facilities. These ratings from India Ratings remain valid and in force.
Consequently, the withdrawal of the CRISIL ratings does not have any impact on Cohance Lifesciences' existing credit facilities or borrowing arrangements. The company continues to maintain its credit ratings from India Ratings.
CRISIL Ratings, in its accompanying rationale dated August 12, 2026, noted that the ratings were withdrawn at the request of the company and after receiving no objection certificates from the banks. The rationale also mentioned that the company was classified as 'non-cooperative' by CRISIL Ratings due to a lack of required information for the rating exercise. CRISIL Ratings had previously migrated its ratings on the bank facilities of Cohance Lifesciences to 'CRISIL BB/Stable/CRISIL A4+ Issuer not cooperating' from 'CRISIL AA-/Positive/CRISIL A1+'. The total bank loan facilities rated by CRISIL amounted to ₹72.5 crore.
The rationale also took note of Cohance Lifesciences' consolidated income of ₹2,302.64 crore and net profit of ₹150.12 crore for fiscal 2026, as well as its first-quarter fiscal 2027 results which reported a consolidated income of ₹434.51 crore and a net loss of ₹45.19 crore. Additionally, it mentioned the disclosure regarding five observations issued by the USFDA in Form FDA 483 following an inspection of its manufacturing facility.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.